Fab’entech offers a modular technological platform which allows the rapid development of effective treatments
to deal with the emergence of new infectious diseases or biological threats.
Proof of Concept
The resurgence of bioterror attack projects involving the use of plant-based biotoxin type agents highlights the importance of protecting ourselves against a potential risk of attack by putting in place a health shield, including the availability of specific and effective medical countermeasures.
In this context, Fab’entech has initiated, in collaboration with the DGA [General Directorate of Armaments], a partnership whose aim is to develop, produce and market medical countermeasures to combat various terror threats.
Emerging infectious diseases
Fab’entech has over 12 years of expertise in the Research and Development of immunotherapies against emerging infectious diseases.
Since 2009, Fab’entech has been involved in programmes intended to combat H5N1 avian influenza, the Ebola haemorrhagic fever and the Crimean-Congo haemorrhagic fever (CCHF). Fab’entech has notably developed a product against the H5N1 avian influenza (Fabenflu®) and a product against Ebola under the aegis of the World Health Organisation (WHO) and with the support of the European Medicines Agency (EMA).
More recently, Fab’entech has been heavily mobilised on the development and production of an anti-SARS-CoV2 treatment, the FabenCOV®, which has strong neutralisation capacities on all variants.
Due to their immediate neutralising action, Fab’entech’s polyclonal antibodies can be used to design therapies that are well suited to the management and treatment of drug intoxications.
Fab’entech develops therapies intended for infected patients or contact cases who are at risk of seeing their condition deteriorate into serious forms of infectious diseases for which the treatment arsenal is insufficient.